scRNA-Seq and Bulk-Seq Analysis Identifies S100A9 Plasma Cells as a Potentially Effective Immunotherapeutic Agent for Multiple Myeloma

References

• Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022;97(8):1086–1107. doi:10.1002/ajh.26590
   PubMed Web of Science ®Google Scholar
• Cowan AJ, Green DJ, Kwok M, et al. Diagnosis and management of multiple myeloma: a review. JAMA. 2022;327(5):464–477. doi:10.1001/jama.2022.0003
   PubMed Web of Science ®Google Scholar
• Di Lernia G, Leone P, Solimando AG, et al. Bortezomib treatment modulates autophagy in multiple myeloma. J Clin Med. 2020;9(2). doi:10.3390/jcm9020552
   PubMed Web of Science ®Google Scholar
• Cohen AD, Raje N, Fowler JA, Mezzi K, Scott EC, Dhodapkar MV. How to train your T cells: overcoming immune dysfunction in multiple myeloma. Clin Cancer Res. 2020;26(7):1541–1554. doi:10.1158/1078-0432.CCR-19-2111
   PubMed Web of Science ®Google Scholar
• Maus MV, Grupp SA, Porter DL, June CH. Antibody-modified T cells: cARs take the front seat for hematologic malignancies. Blood. 2014;123(17):2625–2635. doi:10.1182/blood-2013-11-492231
   PubMed Web of Science ®Google Scholar
• Lipowska-Bhalla G, Gilham DE, Hawkins RE, Rothwell DG. Targeted immunotherapy of cancer with CAR T cells: achievements and challenges. Cancer Immunol Immunother. 2012;61(7):953–962. doi:10.1007/s00262-012-1254-0
   PubMed Web of Science ®Google Scholar
• Han EQ, Li XL, Wang CR, Li TF, Han SY. Chimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challenges. J Hematol Oncol. 2013;6:47. doi:10.1186/1756-8722-6-47
   PubMed Web of Science ®Google Scholar
• You H, Jin S, Wu C, et al. The independent adverse prognostic significance of 1q21 gain/amplification in newly diagnosed multiple myeloma patients. Front Oncol. 2022;12:938392. doi:10.3389/fonc.2022.938392
   PubMed Web of Science ®Google Scholar
• Griffin GK, Wu J, Iracheta-Vellve A, et al. Epigenetic silencing by SETDB1 suppresses tumour intrinsic immunogenicity. Nature. 2021;595(7866):309–314. doi:10.1038/s41586-021-03520-4
   PubMed Web of Science ®Google Scholar
• Singh SR, Rameshwar P, Siegel P. Targeting tumor microenvironment in cancer therapy. Cancer Lett. 2016;380(1):203–204. doi:10.1016/j.canlet.2016.04.009
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gonzalez L, Alonso J. Periostin: a matricellular protein with multiple functions in cancer development and progression. Front Oncol. 2018;8:225. doi:10.3389/fonc.2018.00225
   PubMed Web of Science ®Google Scholar
• Hinshaw DC, Shevde LA. The tumor microenvironment innately modulates cancer progression. Cancer Res. 2019;79(18):4557–4566. doi:10.1158/0008-5472.CAN-18-3962
   PubMed Web of Science ®Google Scholar
• Bermejo DA, Jackson SW, Gorosito-Serran M, et al. Trypanosoma cruzi trans-sialidase initiates a program independent of the transcription factors RORgammat and Ahr that leads to IL-17 production by activated B cells. Nat Immunol. 2013;14(5):514–522. doi:10.1038/ni.2569
   PubMed Web of Science ®Google Scholar
• Kulkarni U, Karsten CM, Kohler T, et al. IL-10 mediates plasmacytosis-associated immunodeficiency by inhibiting complement-mediated neutrophil migration. J Allergy Clin Immunol. 2016;137(5):1487–1497 e1486. doi:10.1016/j.jaci.2015.10.018
   PubMed Web of Science ®Google Scholar
• Shen P, Roch T, Lampropoulou V, et al. IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases. Nature. 2014;507(7492):366–370. doi:10.1038/nature12979
   PubMed Web of Science ®Google Scholar
• Bullwinkle EM, Parker MD, Bonan NF, Falkenberg LG, Davison SP, DeCicco-Skinner KL. Adipocytes contribute to the growth and progression of multiple myeloma: unraveling obesity related differences in adipocyte signaling. Cancer Lett. 2016;380(1):114–121. doi:10.1016/j.canlet.2016.06.010
   PubMed Web of Science ®Google Scholar
• Caers J, Deleu S, Belaid Z, et al. Neighboring adipocytes participate in the bone marrow microenvironment of multiple myeloma cells. Leukemia. 2007;21(7):1580–1584. doi:10.1038/sj.leu.2404658
   PubMed Web of Science ®Google Scholar
• Garcia-Ortiz A, Rodriguez-Garcia Y, Encinas J, et al. The role of tumor microenvironment in multiple myeloma development and progression. Cancers. 2021;13(2). doi:10.3390/cancers13020217
   Web of Science ®Google Scholar
• Dutta AK, Alberge JB, Sklavenitis-Pistofidis R, Lightbody ED, Getz G, Ghobrial IM. Single-cell profiling of tumour evolution in multiple myeloma - opportunities for precision medicine. Nat Rev Clin Oncol. 2022;19(4):223–236. doi:10.1038/s41571-021-00593-y
   PubMed Web of Science ®Google Scholar
• Zavidij O, Haradhvala NJ, Mouhieddine TH, et al. Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma. Nat Cancer. 2020;1(5):493–506. doi:10.1038/s43018-020-0053-3
   PubMedGoogle Scholar
• Butler A, Hoffman P, Smibert P, Papalexi E, Satija R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat Biotechnol. 2018;36(5):411–420. doi:10.1038/nbt.4096
   PubMed Web of Science ®Google Scholar
• Li W, Yuan P, Liu W, et al. Hypoxia-immune-related gene SLC19A1 serves as a potential biomarker for prognosis in multiple myeloma. Front Immunol. 2022;13:843369. doi:10.3389/fimmu.2022.843369
   PubMedGoogle Scholar
• Xiong W, Wu X, Starnes S, et al. An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma. Blood. 2008;112(10):4235–4246. doi:10.1182/blood-2007-10-119123
   PubMed Web of Science ®Google Scholar
• Davis S, Meltzer PS. GEOquery: a bridge between the Gene Expression Omnibus (GEO) and BioConductor. Bioinformatics. 2007;23(14):1846–1847. doi:10.1093/bioinformatics/btm254
   PubMed Web of Science ®Google Scholar
• Jin S, Guerrero-Juarez CF, Zhang L, et al. Inference and analysis of cell-cell communication using CellChat. Nat Commun. 2021;12(1):1088. doi:10.1038/s41467-021-21246-9
   PubMed Web of Science ®Google Scholar
• Charoentong P, Finotello F, Angelova M, et al. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep. 2017;18(1):248–262. doi:10.1016/j.celrep.2016.12.019
   PubMed Web of Science ®Google Scholar
• Barbie DA, Tamayo P, Boehm JS, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature. 2009;462(7269):108–112. doi:10.1038/nature08460
   PubMed Web of Science ®Google Scholar
• Hanzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinf. 2013;14:7. doi:10.1186/1471-2105-14-7
   PubMed Web of Science ®Google Scholar
• Yoshihara K, Shahmoradgoli M, Martinez E, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612. doi:10.1038/ncomms3612
   PubMed Web of Science ®Google Scholar
• Briere G, Darbo E, Thebault P, Uricaru R. Consensus clustering applied to multi-omics disease subtyping. BMC Bioinf. 2021;22(1):361. doi:10.1186/s12859-021-04279-1
   PubMed Web of Science ®Google Scholar
• Wilkerson MD, Hayes DN. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics. 2010;26(12):1572–1573. doi:10.1093/bioinformatics/btq170
   PubMed Web of Science ®Google Scholar
• Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinf. 2008;9:559. doi:10.1186/1471-2105-9-559
   PubMed Web of Science ®Google Scholar
• Liberzon A, Birger C, Thorvaldsdottir H, Ghandi M, Mesirov JP, Tamayo P. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1(6):417–425. doi:10.1016/j.cels.2015.12.004
   PubMed Web of Science ®Google Scholar
• Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16(5):284–287. doi:10.1089/omi.2011.0118
   PubMed Web of Science ®Google Scholar
• Geeleher P, Cox N, Huang RS. pRRophetic: an R package for prediction of clinical chemotherapeutic response from tumor gene expression levels. PLoS One. 2014;9(9):e107468. doi:10.1371/journal.pone.0107468
   PubMed Web of Science ®Google Scholar
• Kyle RA, Rajkumar SV. Treatment of multiple myeloma: a comprehensive review. Clin Lymphoma Myeloma. 2009;9(4):278–288. doi:10.3816/CLM.2009.n.056
   PubMedGoogle Scholar
• Chu VT, Berek C. The establishment of the plasma cell survival niche in the bone marrow. Immunol Rev. 2013;251(1):177–188. doi:10.1111/imr.12011
   PubMed Web of Science ®Google Scholar
• Lannes R, Samur M, Perrot A, et al. In multiple myeloma, high-risk secondary genetic events observed at relapse are present from diagnosis in tiny, undetectable subclonal populations. J Clin Oncol. 2023;41(9):1695–1702. doi:10.1200/JCO.21.01987
   PubMed Web of Science ®Google Scholar
• Ziccheddu B, Biancon G, Bagnoli F, et al. Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma. Blood Adv. 2020;4(5):830–844. doi:10.1182/bloodadvances.2019000779
   PubMed Web of Science ®Google Scholar
• Dutta AK, Fink JL, Grady JP, et al. Subclonal evolution in disease progression from MGUS/SMM to multiple myeloma is characterised by clonal stability. Leukemia. 2019;33(2):457–468. doi:10.1038/s41375-018-0206-x
   PubMed Web of Science ®Google Scholar
• Meng L, Tang Q, Zhao J, et al. S100A9 derived from myeloma associated myeloid cells promotes TNFSF13B/TNFRSF13B-dependent proliferation and survival of myeloma cells. Front Oncol. 2021;11:691705. doi:10.3389/fonc.2021.691705
   PubMed Web of Science ®Google Scholar
• Lin C, Garcia-Gerique L, Bonner EE, et al. S100A8/S100A9 promote progression of multiple myeloma via expansion of megakaryocytes. Cancer Res Commun. 2023;3(3):420–430. doi:10.1158/2767-9764.CRC-22-0368
   PubMedGoogle Scholar
• Tanaka M, Siemann DW. Gas6/Axl signaling pathway in the tumor immune microenvironment. Cancers. 2020;12(7). doi:10.3390/cancers12071850
   Web of Science ®Google Scholar
• Tu J, Tan X, Chen Y, et al. Growth arrest-specific transcript 5 represses endometrial cancer development by promoting antitumor function of tumor-associated macrophages. Cancer Sci. 2022;113(8):2496–2512. doi:10.1111/cas.15390
   PubMed Web of Science ®Google Scholar
• Bozkaya G, Korhan P, Cokakli M, et al. Cooperative interaction of MUC1 with the HGF/c-Met pathway during hepatocarcinogenesis. Mol Cancer. 2012;11:64. doi:10.1186/1476-4598-11-64
   PubMed Web of Science ®Google Scholar
• Menard L, Parker PJ, Kermorgant S. Receptor tyrosine kinase c-Met controls the cytoskeleton from different endosomes via different pathways. Nat Commun. 2014;5:3907. doi:10.1038/ncomms4907
   PubMed Web of Science ®Google Scholar
• Szturz P, Raymond E, Abitbol C, Albert S, de Gramont A, Faivre S. Understanding c-MET signalling in squamous cell carcinoma of the head & neck. Crit Rev Oncol Hematol. 2017;111:39–51. doi:10.1016/j.critrevonc.2017.01.004
   PubMed Web of Science ®Google Scholar
• International Cancer Genome Consortium PedBrain Tumor P. Recurrent MET fusion genes represent a drug target in pediatric glioblastoma. Nat Med. 2016;22(11):1314–1320. doi:10.1038/nm.4204
   PubMed Web of Science ®Google Scholar
• Kim B, Jung N, Lee S, Sohng JK, Jung HJ. Apigenin inhibits cancer stem cell-like phenotypes in human glioblastoma cells via suppression of c-Met signaling. Phytother Res. 2016;30(11):1833–1840. doi:10.1002/ptr.5689
   PubMed Web of Science ®Google Scholar
• Sangro B, Sarobe P, Hervas-Stubbs S, Melero I. Advances in immunotherapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2021;18(8):525–543. doi:10.1038/s41575-021-00438-0
   PubMed Web of Science ®Google Scholar
• Raj S, Kesari KK, Kumar A, et al. Molecular mechanism(s) of regulation(s) of c-MET/HGF signaling in head and neck cancer. Mol Cancer. 2022;21(1):31. doi:10.1186/s12943-022-01503-1
   PubMed Web of Science ®Google Scholar
• Aloe CA, Leong TL, Wimaleswaran H, et al. Excess iron promotes emergence of foamy macrophages that overexpress ferritin in the lungs of silicosis patients. Respirology. 2022;27(6):427–436. doi:10.1111/resp.14230
   PubMed Web of Science ®Google Scholar
• Baranano DE, Rao M, Ferris CD, Snyder SH. Biliverdin reductase: a major physiologic cytoprotectant. Proc Natl Acad Sci U S A. 2002;99(25):16093–16098. doi:10.1073/pnas.252626999
   PubMed Web of Science ®Google Scholar
• Conus S, Simon HU. Cathepsins and their involvement in immune responses. Swiss Med Wkly. 2010;140:w13042. doi:10.4414/smw.2010.13042
   PubMed Web of Science ®Google Scholar
• Laight BJ, Jawa NA, Tyryshkin K, Maslove DM, Boyd JG, Greer PA. Establishing the role of the FES tyrosine kinase in the pathogenesis, pathophysiology, and severity of sepsis and its outcomes. Front Immunol. 2023;14:1145826. doi:10.3389/fimmu.2023.1145826
   PubMed Web of Science ®Google Scholar
• Weir MC, Hellwig S, Tan L, Liu Y, Gray NS, Smithgall TE. Dual inhibition of Fes and Flt3 tyrosine kinases potently inhibits Flt3-ITD+ AML cell growth. PLoS One. 2017;12(7):e0181178. doi:10.1371/journal.pone.0181178
   PubMed Web of Science ®Google Scholar
• Craig AW. FES/FER kinase signaling in hematopoietic cells and leukemias. Front Biosci. 2012;17(3):861–875. doi:10.2741/3961
   Google Scholar
• Peroutka RJ, Buzza MS, Mukhopadhyay S, Johnson TA, Driesbaugh KH, Antalis TM. Testisin/Prss21 deficiency causes increased vascular permeability and a hemorrhagic phenotype during luteal angiogenesis. PLoS One. 2020;15(6):e0234407. doi:10.1371/journal.pone.0234407
   PubMed Web of Science ®Google Scholar
• Richardson RB, Ohlson MB, Eitson JL, et al. A CRISPR screen identifies IFI6 as an ER-resident interferon effector that blocks flavivirus replication. Nat Microbiol. 2018;3(11):1214–1223. doi:10.1038/s41564-018-0244-1
   PubMed Web of Science ®Google Scholar
• Brott AS, Clarke AJ. Peptidoglycan O-acetylation as a virulence factor: its effect on lysozyme in the innate immune system. Antibiotics. 2019;8(3). doi:10.3390/antibiotics8030094
   Google Scholar
• Ragland SA, Criss AK. From bacterial killing to immune modulation: recent insights into the functions of lysozyme. PLoS Pathog. 2017;13(9):e1006512. doi:10.1371/journal.ppat.1006512
   PubMed Web of Science ®Google Scholar
• Shen CC, Kang YH, Yu L, et al. Human testis-expressed sequence 101 is limitedly distributed in germinal epithelium of testis and disappears in seminoma. Biol Res. 2014;47(1):52. doi:10.1186/0717-6287-47-52
   PubMedGoogle Scholar
• van Lent PL, Grevers L, Blom AB, et al. Myeloid-related proteins S100A8/S100A9 regulate joint inflammation and cartilage destruction during antigen-induced arthritis. Ann Rheum Dis. 2008;67(12):1750–1758. doi:10.1136/ard.2007.077800
   PubMed Web of Science ®Google Scholar
• Schonthaler HB, Guinea-Viniegra J, Wculek SK, et al. S100A8-S100A9 protein complex mediates psoriasis by regulating the expression of complement factor C3. Immunity. 2013;39(6):1171–1181. doi:10.1016/j.immuni.2013.11.011
   PubMed Web of Science ®Google Scholar
• Brown KL, Lubieniecka JM, Armaroli G, et al. S100A12 serum levels and PMN counts are elevated in childhood systemic vasculitides especially involving proteinase 3 specific anti-neutrophil cytoplasmic antibodies. Front Pediatr. 2018;6:341. doi:10.3389/fped.2018.00341
   PubMed Web of Science ®Google Scholar
• Foell D, Kucharzik T, Kraft M, et al. Neutrophil derived human S100A12 (EN-RAGE) is strongly expressed during chronic active inflammatory bowel disease. Gut. 2003;52(6):847–853. doi:10.1136/gut.52.6.847
   PubMed Web of Science ®Google Scholar
• Li T, Wang Y, Zhu C, Yang Y, Long C, Chen Q. Identification of Ribonuclease 6 as an immunoinflammatory key gene associated with the glomerular injury in diabetic nephropathy. Sci Rep. 2022;12(1):19709. doi:10.1038/s41598-022-24289-0
   PubMed Web of Science ®Google Scholar
• Mitchell ES, Conus N, Kaput J. B vitamin polymorphisms and behavior: evidence of associations with neurodevelopment, depression, schizophrenia, bipolar disorder and cognitive decline. Neurosci Biobehav Rev. 2014;47:307–320. doi:10.1016/j.neubiorev.2014.08.006
   PubMed Web of Science ®Google Scholar
• Zhang K, Xu P, Sowers JL, et al. Proteome analysis of hypoxic glioblastoma cells reveals sequential metabolic adaptation of one-carbon metabolic pathways. Mol Cell Proteomics. 2017;16(11):1906–1921. doi:10.1074/mcp.RA117.000154
   PubMed Web of Science ®Google Scholar